FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

October 27, 2025

Lead presenter Passi Jänne, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025. In this exploratory overall survival (OS) analysis from the Phase III FLAURA2 study in advanced EGFR-mutated non-small cell lung cancer (NSCLC), first-line treatment with osimertinib plus platinum-pemetrexed chemotherapy showed a consistent survival benefit compared with osimertinib alone across patients with poorer prognostic factors. The combination led to longer median OS and reduced risk of death regardless of baseline features such as central nervous system metastases, TP53 alterations, or specific EGFR mutation types, reinforcing that adding chemotherapy up front improves outcomes in high-risk EGFR-mutated NSCLC groups.